Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gosselies – page 60

1 856 clinical trials in Gosselies, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gosselies at a glance
1 856
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 856 trials in Gosselies

Open in trial search

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Schizophrenia

Not yet recruiting

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:European Group for Research in Schizophrenia Stichting

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not yet recruiting

Clinical trial of subcutaneous infliximab in patients with perianal fistulizing Crohn’s disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:CHU De Liege

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Narcolepsy

Not yet recruiting

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gosselies

What the registry says about research in the country

01 Immunology Research

Ongoing studies focusing on SARS-CoV-2 immunity patterns in vulnerable populations, particularly examining antibody responses in immunocompromised individuals.

  • Antibody Response Monitoring
  • Variant of Concern Analysis
  • Long-term Immunity Assessment

The research encompasses diverse patient groups including nursing home residents, dialysis patients, and transplant recipients, providing valuable insights into COVID-19 immunity in at-risk populations.

02 Transplant Medicine

Specialized investigation of immune responses in kidney and lung transplant patients, contributing to understanding COVID-19 vulnerability in transplant recipients.

  • Post-transplant Immunity
  • Immunosuppression Impact
  • Patient-specific Response Patterns

This longitudinal study in Belgium aims to enhance protective strategies for transplant recipients during the pandemic.

03 Geriatric Medicine

Comprehensive evaluation of COVID-19 immunity in elderly populations, with special attention to nursing home residents.

  • Age-related Immune Response
  • Elderly Population Protection
  • Long-term Immunity Monitoring

Research focused on understanding immune system responses in older adults to improve prevention strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.